Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will look at two FDA approved medications that improve how the pancreas works in patients with Type 2 Diabetes. In order to understand how these medications work in patients with diabetes we must first measure the normal response in healthy volunteers without diabetes. We will be looking at the body's normal physiological response to low blood sugar and whether this will be modified by these medicationsThe hypothesis would be that glimepiride induced insulin secretion will be inhibited by hypoglycemia.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vanderbilt University; Vanderbilt University Medical Center
• Treatments: Glimepiride; Glyburide

Criteria

Inclusion Criteria:

• Healthy male and female subjects aged 30-60

• Body Mass Index 21-30 kg/m2

• All potential volunteers will have routine blood test to screen for hepatic, renal, and hematological abnormalities

• EKG treadmill stress test for volunteers over 40 years of age.

• Female volunteers of childbearing potential will undergo HCG pregnancy test.

Exclusion Criteria:

• Prior or current history of poor health

• Abnormal results following screening tests

• Pregnancy

• History of allergy to sulfonylurea or related drugs